A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Clinical trial NCT06198751 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06198751
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-05
- Primary completion
- 2025-05-08
- Enrollment
- 104
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.